Biorchestra: BIORCHESTRA: RAISES $45M IN SERIES C FUNDING

Biorchestra, a Daejeon, South Korea, and Cambridge, Massachusetts, USA-based RNA therapeutics company, raised $45M in Series C funding The company intends to use the funds to support the expansion of research and development activities and product pipeline, completion of GMP facility The company is an innovative biotech developing ribonucleic acid (RNA) based therapeutics The BMD is a therapeutic agent development platform that can control microRNAs that regulate multiple messenger RNAs (mRNAs) involved in pathological factors related to diseases The company has developed proprietary drug delivery system (BDDS™) for commercial drug development Delivering the ASO via intravenous injection route, they observed target microRNA knock-down efficacy not only in cortex but also deep brain such as hippocampus even striatum and spinal cord as well TAGS:BIORCHESTRA Share DON'T MISS FINTECH BIORCHESTRA: RAISES $45M IN SERIES C FUNDING FINTECH AUSTRALIAN STRATEGIC MATERIALS: SIGNS EXCLUSIVE DEAL WITH HYUNDAI ENGINEERING